Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25551021 | 0.88 | KDM4E (0.58) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15426215 | 0.86 | CSNK1A1 (0.59) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6492107 | 0.86 | CCNB2 (0.56) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL17559719 | 0.85 | MEN1 (0.65) | KDM4EMEN1KMT2AALDH1A1PAX8 | |
| SCHEMBL7762324 | 0.84 | TUBB4A (0.64) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL30791409 | 0.81 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1PAX8 | |
| SCHEMBL22204569 | 0.81 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1PAX8 | |
| SCHEMBL29050101 | 0.81 | MEN1 (0.61) | KDM4EMEN1KMT2AALDH1A1PAX8 | |
| SCHEMBL5438097 | 0.81 | NR4A2 (0.69) | KDM4EMEN1KMT2AALDH1A1TUBB4A | |
| SCHEMBL10832846 | 0.80 | KDM4E (0.50) | KDM4EMEN1KMT2AALDH1A1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114232013-B | Method for synthesizing indoloquinoline compounds under electrochemical condition | 华南理工大学 | 2023-04-21 | — | — | CN | claimed |
| CN-114232013-A | Method for synthesizing indoloquinoline compound under electrochemical condition | 华南理工大学 | 2022-03-25 | — | — | CN | claimed |
| JP-59175429-A | — | — | None | — | — | JP | disclosed |
| CN-114232013-B | Method for synthesizing indoloquinoline compounds under electrochemical condition | 华南理工大学 | 2023-04-21 | — | — | CN | disclosed |
| CN-114232013-A | Method for synthesizing indoloquinoline compound under electrochemical condition | 华南理工大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-110799214-A | Blood purification with alkalizer | 国立大学法人东北大学 | 2020-02-14 | — | — | CN | disclosed |
| US-6951881-B2 | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-18 | — | — | US | disclosed |
| US-4814344-A | ANTIEMENTICS, ANTIPSYCHOTICS | GLAXO GROUP LIMITED | 1989-03-21 | — | — | US | disclosed |
| EP-0266899-A2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1988-05-11 | — | — | EP | disclosed |
| JP-S59175429-A | PHARMACEUTICAL COMPOSITION HAVING CARCINOSTATIC ACTIVITY | MOCHIDA PHARMACEUT CO LTD | 1984-10-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | KDM4E 3679/4885MEN1 3034/4885KMT2A 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.